IL298200A - Combination therapy for treatment of myeloproliferative neoplasms - Google Patents
Combination therapy for treatment of myeloproliferative neoplasmsInfo
- Publication number
- IL298200A IL298200A IL298200A IL29820022A IL298200A IL 298200 A IL298200 A IL 298200A IL 298200 A IL298200 A IL 298200A IL 29820022 A IL29820022 A IL 29820022A IL 298200 A IL298200 A IL 298200A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- day
- compound
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034214P | 2020-06-03 | 2020-06-03 | |
| PCT/US2020/050753 WO2021247064A1 (en) | 2020-06-03 | 2020-09-14 | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298200A true IL298200A (en) | 2023-01-01 |
Family
ID=72659928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298200A IL298200A (en) | 2020-06-03 | 2020-09-14 | Combination therapy for treatment of myeloproliferative neoplasms |
Country Status (23)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251457T1 (hr) * | 2020-06-03 | 2026-01-02 | Incyte Corporation | Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi |
| EP4297750A1 (en) * | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| WO2024039883A2 (en) * | 2022-08-19 | 2024-02-22 | Translational Drug Development Llc | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms |
| WO2024144258A1 (ko) * | 2022-12-28 | 2024-07-04 | 주식회사 삼양홀딩스 | 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법 |
| EP4734995A1 (en) * | 2023-06-28 | 2026-05-06 | Board of Regents, The University of Texas System | Quinoline carboxamides for use in the treatment of mpn |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| SMT202000133T1 (it) * | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| CN109715625B (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| HRP20251457T1 (hr) * | 2020-06-03 | 2026-01-02 | Incyte Corporation | Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi |
-
2020
- 2020-09-14 HR HRP20251457TT patent/HRP20251457T1/hr unknown
- 2020-09-14 MA MA59868A patent/MA59868B1/fr unknown
- 2020-09-14 EP EP20781202.5A patent/EP4161528B1/en active Active
- 2020-09-14 WO PCT/US2020/050753 patent/WO2021247064A1/en not_active Ceased
- 2020-09-14 SI SI202030684T patent/SI4161528T1/sl unknown
- 2020-09-14 RS RS20251189A patent/RS67440B1/sr unknown
- 2020-09-14 IL IL298200A patent/IL298200A/en unknown
- 2020-09-14 DK DK20781202.5T patent/DK4161528T3/da active
- 2020-09-14 PT PT207812025T patent/PT4161528T/pt unknown
- 2020-09-14 EP EP25209713.4A patent/EP4691563A3/en active Pending
- 2020-09-14 ES ES20781202T patent/ES3058891T3/es active Active
- 2020-09-14 KR KR1020227046429A patent/KR20230031242A/ko active Pending
- 2020-09-14 MD MDE20230400T patent/MD4161528T2/ro unknown
- 2020-09-14 FI FIEP20781202.5T patent/FI4161528T3/fi active
- 2020-09-14 CA CA3184633A patent/CA3184633A1/en active Pending
- 2020-09-14 MX MX2022015220A patent/MX2022015220A/es unknown
- 2020-09-14 PL PL20781202.5T patent/PL4161528T3/pl unknown
- 2020-09-14 SM SM20260021T patent/SMT202600021T1/it unknown
- 2020-09-14 LT LTEPPCT/US2020/050753T patent/LT4161528T/lt unknown
- 2020-09-14 JP JP2022574520A patent/JP7669396B2/ja active Active
- 2020-09-14 PH PH1/2022/553276A patent/PH12022553276A1/en unknown
- 2020-09-14 AU AU2020451061A patent/AU2020451061A1/en active Pending
- 2020-09-14 CN CN202080101656.6A patent/CN115835868A/zh active Pending
-
2022
- 2022-12-01 CL CL2022003409A patent/CL2022003409A1/es unknown
-
2025
- 2025-04-16 JP JP2025067272A patent/JP2025111539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025111539A (ja) | 2025-07-30 |
| MD4161528T2 (ro) | 2026-03-31 |
| PH12022553276A1 (en) | 2024-02-19 |
| DK4161528T3 (da) | 2025-11-24 |
| JP2023529365A (ja) | 2023-07-10 |
| CL2022003409A1 (es) | 2023-05-26 |
| PT4161528T (pt) | 2026-01-23 |
| FI4161528T3 (fi) | 2025-12-12 |
| AU2020451061A1 (en) | 2022-12-15 |
| KR20230031242A (ko) | 2023-03-07 |
| PL4161528T3 (pl) | 2026-03-16 |
| EP4161528A1 (en) | 2023-04-12 |
| RS67440B1 (sr) | 2025-12-31 |
| HRP20251457T1 (hr) | 2026-01-02 |
| SI4161528T1 (sl) | 2026-01-30 |
| WO2021247064A1 (en) | 2021-12-09 |
| MX2022015220A (es) | 2023-03-08 |
| CN115835868A (zh) | 2023-03-21 |
| EP4691563A3 (en) | 2026-04-01 |
| CA3184633A1 (en) | 2021-12-09 |
| ES3058891T3 (en) | 2026-03-13 |
| SMT202600021T1 (it) | 2026-03-09 |
| EP4691563A2 (en) | 2026-02-11 |
| JP7669396B2 (ja) | 2025-04-28 |
| LT4161528T (lt) | 2026-02-10 |
| EP4161528B1 (en) | 2025-11-05 |
| MA59868B1 (fr) | 2025-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4161528B1 (en) | Combination of ruxolitinib with incb057643 for use in the treatment of myeloproliferative neoplasms | |
| US20260137695A1 (en) | Combination therapy for treatment of myeloproliferative neoplasms | |
| TWI702057B (zh) | 盧梭利替尼之緩釋性劑型 | |
| EP3750530B1 (en) | Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer | |
| EP4410375A2 (en) | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | |
| CN110913861B (zh) | G1t38的形态学形式及其制造方法 | |
| CN116157403B (zh) | 曲拉西利的形态及其制造方法 | |
| CN118201615A (zh) | 喹唑啉酮化合物用于治疗癌症的新用途 | |
| CN119403808A (zh) | 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂 | |
| TWI880995B (zh) | 急性骨髓性白血病或骨髓發育不良症候群的治療 | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| KR20240016298A (ko) | 재발성 원발성 cns 신생물에 대한 용도 및 방법 | |
| TW201922256A (zh) | 治療淋巴樣惡性疾病之方法 | |
| JP2025061387A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| JP2024542248A (ja) | Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法 | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| US20230165863A1 (en) | Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors | |
| HK40112852A (en) | Pharmaceutical for treating or preventing cancer | |
| TW202608439A (zh) | 治療具有ａｓｘｌ１突變之個體之癌症的方法 | |
| HK40112620A (en) | Novel use of quinazolinone compound for the treatment of cancer | |
| TW202535398A (zh) | 用於治療癌症之包含光學活性氮雜雙環衍生物之醫藥 | |
| CN112294814A (zh) | 用于治疗胶质母细胞瘤的喹啉衍生物 |